David T. Doherty, Chief Financial Officer of Surgery Partners (NASDAQ:SGRY), executed a single sale of 8,867 shares of common stock on March 16, 2026, at $12.50 per share, producing gross proceeds of $110,837. The transaction took place while the stock was trading close to its 52-week low of $12.25 and after a year in which the share price has declined 49%.
Following this disposition, Doherty directly holds 221,679 shares of Surgery Partners. Company filings indicate the sale was made to satisfy tax withholding obligations associated with the vesting of restricted stock on March 4, 2026. The sale is presented in the filings as a tax-related event rather than a discretionary liquidity-driven trade.
Market commentary included in industry analysis notes that at current market prices the stock appears slightly undervalued, with analysts anticipating the company will return to profitability this year. That same analysis platform offers eight additional ProTips for investors seeking further perspective on SGRY.
Separately, Surgery Partners has been active on the corporate governance front. The company appointed Lloyd Dean, the former CEO of CommonSpirit Health, as an independent director to its board of directors. The appointment comes amid a campaign by activist investor Ortelius Advisors, which has urged significant changes at the company, including management adjustments and a broad strategic review.
Analyst responses to the companys recent performance and outlook have varied. UBS has reiterated a Buy rating on Surgery Partners with a price target of $21, maintaining its positive stance despite the activist campaign. RBC Capital trimmed its price target to $20 from $31 while keeping an Outperform rating, citing softer-than-expected guidance for 2026. TD Cowen also lowered its price target to $20 from $28 and maintained a Buy rating; the firm pointed to adjusted EBITDA-NCI results that came in 6% below consensus estimates, attributing the shortfall to a negative insurance mix shift and localized market issues at three surgical hospitals.
These filings, analyst notes, and the new board appointment together underscore the combination of internal capital events, external shareholder pressure, and performance shortfalls that have placed Surgery Partners under heightened scrutiny. The companys strategic direction and operational execution remain focal points for investors and analysts as it works through guidance and profit forecasts for the year.
Summary
Chief Financial Officer David T. Doherty sold 8,867 shares on March 16, 2026, at $12.50 per share to cover tax withholding from restricted stock vesting earlier in March. The transaction occurred while the share price sits near its 52-week low. Meanwhile, Surgery Partners added an independent director and continues to face activism and mixed analyst revisions.
Key points
- The sale of 8,867 shares by CFO David T. Doherty generated $110,837 and was executed to satisfy tax withholding from restricted stock vested on March 4, 2026.
- SGRY shares trade near a 52-week low of $12.25 and have fallen 49% over the past year, prompting varied analyst reactions and price-target adjustments.
- Corporate governance developments include the appointment of Lloyd Dean as an independent board director amid pressure from activist investor Ortelius Advisors; analysts UBS, RBC Capital, and TD Cowen have issued differing ratings and target revisions.
Risks and uncertainties
- Operational and financial performance risk - Adjusted EBITDA-NCI results were reported 6% below consensus estimates, linked to insurance mix shifts and market-specific issues at three surgical hospitals, which could affect near-term profitability.
- Strategic and governance uncertainty - Activist investor Ortelius Advisors has called for leadership and strategic changes, introducing potential boardroom and management shifts that may impact execution.
- Market valuation pressure - The stock is trading near its 52-week low and has declined materially year-over-year, creating valuation risk for shareholders and influencing analyst price-target revisions.